3rd ADC Payload Summit 2026

The 3rd ADC Payload Summit is the only dedicated forum focused exclusively on payload innovation, bringing together 70+ leaders across payload chemistry, discovery biology, translational science, and R&D to tackle challenges in diversifying ADC payloads as warheads for overcoming tumor resistance, with optimized efficacy, potency, and differentiated mechanisms of action. As the ADC field becomes increasingly crowded with TOPO-1 and tubulin-based payloads, this summit addresses the pressure to identify differentiated mechanisms that can overcome resistance, improve therapeutic index, and deliver meaningful clinical advantage. Through deep-dive workshops, case studies, panel discussions, and curated matchmaking roundtables, attendees will explore novel payload classes, dual-payload strategies, resistance mechanisms, translational modelling, and emerging approaches beyond traditional cytotoxicity. The summit aims to provide solutions to key challenges around potency, safety, translation, and clinical success to deliver more effective therapies for patients. It is a dedicated forum to learn, network, and partner with leaders advancing next-generation ADC payloads, novel mechanisms of action, and innovative linker-payload strategies, exploring emerging modalities including dual-payload ADCs, molecular glues, degrader conjugates, RNA splicing payloads, and NMT inhibitors. The summit is designed for teams tackling key scientific challenges shaping payload selection and clinical success, including overcoming resistance, improving therapeutic index, optimizing linker-payload systems, evaluating novel mechanisms of action, and translating differentiated payload strategies into clinical development.